vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 1.4%, a 9.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 9.7%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ACAD vs ANIP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $247.1M |
| Net Profit | $3.6M | $27.5M |
| Gross Margin | — | — |
| Operating Margin | -1.7% | 14.1% |
| Net Margin | 1.4% | 11.1% |
| Revenue YoY | 9.7% | 29.6% |
| Net Profit YoY | — | 367.5% |
| EPS (diluted) | $0.02 | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | — | ||
| Q4 25 | $284.0M | $247.1M | ||
| Q3 25 | $278.6M | $227.8M | ||
| Q2 25 | $264.6M | $211.4M | ||
| Q1 25 | $244.3M | $197.1M | ||
| Q4 24 | $259.6M | $190.6M | ||
| Q3 24 | $250.4M | $148.3M | ||
| Q2 24 | $242.0M | $138.0M |
| Q1 26 | $3.6M | — | ||
| Q4 25 | $273.6M | $27.5M | ||
| Q3 25 | $71.8M | $26.6M | ||
| Q2 25 | $26.7M | $8.5M | ||
| Q1 25 | $19.0M | $15.7M | ||
| Q4 24 | $143.7M | $-10.3M | ||
| Q3 24 | $32.8M | $-24.2M | ||
| Q2 24 | $33.4M | $-2.3M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | -1.7% | — | ||
| Q4 25 | 6.1% | 14.1% | ||
| Q3 25 | 12.8% | 15.9% | ||
| Q2 25 | 12.2% | 6.6% | ||
| Q1 25 | 7.9% | 13.3% | ||
| Q4 24 | 59.1% | -2.3% | ||
| Q3 24 | 12.6% | -13.8% | ||
| Q2 24 | 12.6% | 3.7% |
| Q1 26 | 1.4% | — | ||
| Q4 25 | 96.3% | 11.1% | ||
| Q3 25 | 25.8% | 11.7% | ||
| Q2 25 | 10.1% | 4.0% | ||
| Q1 25 | 7.8% | 8.0% | ||
| Q4 24 | 55.4% | -5.4% | ||
| Q3 24 | 13.1% | -16.3% | ||
| Q2 24 | 13.8% | -1.7% |
| Q1 26 | $0.02 | — | ||
| Q4 25 | $1.61 | $1.14 | ||
| Q3 25 | $0.42 | $1.13 | ||
| Q2 25 | $0.16 | $0.36 | ||
| Q1 25 | $0.11 | $0.69 | ||
| Q4 24 | $0.86 | $-0.45 | ||
| Q3 24 | $0.20 | $-1.27 | ||
| Q2 24 | $0.20 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $285.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $540.7M |
| Total Assets | $1.6B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | $285.6M | ||
| Q3 25 | $258.0M | $262.6M | ||
| Q2 25 | $253.6M | $217.8M | ||
| Q1 25 | $217.7M | $149.8M | ||
| Q4 24 | $319.6M | $144.9M | ||
| Q3 24 | $155.1M | $145.0M | ||
| Q2 24 | $177.1M | $240.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $540.7M | ||
| Q3 25 | $917.3M | $505.8M | ||
| Q2 25 | $822.4M | $436.8M | ||
| Q1 25 | $765.2M | $418.6M | ||
| Q4 24 | $732.8M | $403.7M | ||
| Q3 24 | $577.2M | $405.9M | ||
| Q2 24 | $516.7M | $455.8M |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.3B | ||
| Q3 24 | $976.9M | $1.3B | ||
| Q2 24 | $914.1M | $920.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $30.4M |
| Free Cash FlowOCF − Capex | — | $29.1M |
| FCF MarginFCF / Revenue | — | 11.8% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | — | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $30.4M | ||
| Q3 25 | $74.3M | $44.1M | ||
| Q2 25 | $64.0M | $75.8M | ||
| Q1 25 | $20.3M | $35.0M | ||
| Q4 24 | $40.4M | $15.9M | ||
| Q3 24 | $63.2M | $12.5M | ||
| Q2 24 | $25.0M | $17.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $29.1M | ||
| Q3 25 | $73.9M | $38.0M | ||
| Q2 25 | — | $71.8M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | $63.2M | $7.7M | ||
| Q2 24 | — | $13.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 11.8% | ||
| Q3 25 | 26.5% | 16.7% | ||
| Q2 25 | — | 34.0% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | 25.2% | 5.2% | ||
| Q2 24 | — | 9.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.1% | 2.7% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | 0.0% | 3.2% | ||
| Q2 24 | — | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 1.10× | ||
| Q3 25 | 1.03× | 1.66× | ||
| Q2 25 | 2.40× | 8.87× | ||
| Q1 25 | 1.07× | 2.23× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
Segment breakdown not available.
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
